Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000804721 | SCV000944643 | likely benign | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2023-11-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002422755 | SCV002726902 | uncertain significance | Inborn genetic diseases | 2022-03-28 | criteria provided, single submitter | clinical testing | The p.R695Q variant (also known as c.2084G>A), located in coding exon 11 of the INF2 gene, results from a G to A substitution at nucleotide position 2084. The arginine at codon 695 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and glutamine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV000804721 | SCV002776399 | uncertain significance | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2021-10-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003156294 | SCV003845656 | likely benign | not provided | 2020-10-26 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Breakthrough Genomics, |
RCV003156294 | SCV005193489 | uncertain significance | not provided | criteria provided, single submitter | not provided |